Advaxis – Confidential Separation Agreement (July 7th, 2017)
THIS AGREEMENT (the "Agreement") is entered into as of the Effective Date, as defined in Paragraph 6 hereof, by and between Advaxis, Inc. (the "Company") and Daniel J. O'Connor ("Executive"). Together, the Company and Executive may be referred to hereinafter as the "Parties".
Advaxis – Advaxis, Inc. PLACEMENT AGENCY AGREEMENT (August 16th, 2016)
Champions Biotechnlg – Note Purchase Agreement (December 5th, 2014)
THIS NOTE PURCHASE AGREEMENT (this "Agreement"), made as of the date set forth on the signature page hereto, is between Champions Oncology, Inc., a Delaware corporation (the "Company"), and the other party hereto (the "Purchaser").
Champions Biotechnlg – Contract (December 5th, 2014)
THIS NOTE AND, IF APPLICABLE, THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE SECURITIES LAWS OF ANY STATE, AND MAY BE OFFERED AND SOLD ONLY IN ACCORDANCE WITH THAT CERTAIN NOTE PURCHASE AGREEMENT BETWEEN THE ISSUER AND THE OTHER PARTY NAMED THEREIN, AND IF REGISTERED AND QUALIFIED PURSUANT TO THE RELEVANT PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR IF THE ISSUER IS PROVIDED AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER THAT REGISTRATION AND QUALIFICATION UNDER FEDERAL AND STATE SECURITIES LAWS IS NOT REQUIRED.
EpiCept Corporation – Amendment Agreement (August 14th, 2014)
THIS AMENDMENT AGREEMENT (the "Agreement") is dated as of August 13, 2014, by and between Immune Pharmaceuticals Inc., a Delaware corporation with offices located at Cambridge Innovation Center, One Broadway, 14th Floor, Cambridge, MA 02142 (the "Company"), and the investor signatory hereto (the "Investor").
EpiCept Corporation – June 4, 2014 (June 6th, 2014)
The purpose of this letter is to provide you with an employment offer specifying the terms and conditions of your employment with Immune Pharmaceuticals Inc. as follows:
Champions Biotechnlg – Put Right Agreement (February 6th, 2014)
This Put Right Agreement (this "Agreement"), by and among Champions Oncology, Inc. (the "Company"), Joel Ackerman ("Ackerman") and Ronnie Morris ("Morris"), is dated effective as of January 29, 2014.
Champions Biotechnlg – Laboratory Located At: Science + Technology Park at Johns Hopkins (November 1st, 2011)
On behalf of Champions Oncology, Inc., we are pleased to offer you the position of Executive Vice President and Chief Financial Officer. You will be reporting to Joel Ackerman, Chief Executive Officer of Champions Oncology, Inc. This letter outlines the terms of your proposed employment as a full-time employee as follows:
Champions Biotechnlg – Schedule a to Agreement With Dr. Ronnie Morris Option Terms (October 29th, 2010)
Champions Biotechnlg – Schedule a to Agreement With Joel Ackerman Option Terms (October 29th, 2010)
Champions Biotechnlg – Consulting Agreement (August 27th, 2009)
THIS CONSULTING AGREEMENT (Agreement) made this May 18, 2009, by and between James Martell, (the Consultant) whose address is 2200 Wilson Blvd., Suite 102-316, Arlington, VA, and CHAMPIONS BIOTECHNOLOGY, INC. (the Company) whose principal office is Science & Technology Park at Johns Hopkins, 855 N. Wolfe Street, Baltimore, MD.
Alfacell Corporation – Presented By: Kuslima Shogen, Chairman and CEO Lawrence A. Kenyon, Executive VP and CFO ALFACELL CORPORATION (June 5th, 2007)